New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
14:45 EDTAGNEarnings Preview: Allergan up approximately 15% year-to-date
Allergan (AGN) is scheduled to report Q4 earnings before the market open on Tuesday February 5, with a conference call scheduled for 11:00 am ET. Allergan is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products... EXPECTATIONS: Analysts are looking for EPS of $1.18 on revenue of $1.51B, according to First Call. The consensus range for EPS is $1.13-$1.21 on revenue of $1.48- $1.53B... LAST QUARTER: Allergan reported Q3 EPS of $1.06 against estimates of $1.04 on revenue of $1.41B against estimates of $1.43B. At the time of its Q3 earnings release, Allergan gave Q4 EPS guidance of $1.18-$1.20 against consensus estimates of $1.20 on revenue of $1.47B-$1.55B on consensus estimates of $1.51B... STREET RESEARCH: In a research note from February 4, Buckingham said it is keeping its Buy rating on Allergan shares on attractive longer term growth prospects, but noted that with shares up ~ 17% year-to-date, some volatility in share price should be expected. The firm also noted that it would be more aggressive on shares with any potential weakness. On January 25, Leerink raised Allergan's price target to $116-$117 from $103-$104 to reflect its positive view of recent acquisitions and long-term prospects for the company. Leerink kept an Outperform rating on the stock... PRICE ACTION: Allergan shares are up approximately 15% since January 1. In late afternoon trading, Allergan shares are down about 1.5% to $105.30.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
07:04 EDTAGNAllergan initiated with a Buy at Sterne Agee
Target $142.
April 11, 2014
18:44 EDTAGNJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use